Grail names new CEO as Bob Ragusa retiresnews2026-03-13T03:23:06+00:00March 13th, 2026|Endpoints News|
Roche, Element and Ultima push toward the $100 genomenews2026-03-05T20:17:26+00:00March 5th, 2026|Endpoints News|
Why did my doctor push Grail’s dubious cancer test?news2026-02-26T17:09:28+00:00February 26th, 2026|Endpoints News|
Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Actnews2026-02-23T19:56:05+00:00February 23rd, 2026|Endpoints News|
Grail’s cancer test faces new uncertainty after UK studynews2026-02-20T20:09:44+00:00February 20th, 2026|Endpoints News|
Grail’s cancer test misses primary study goal in UK studynews2026-02-20T03:19:15+00:00February 20th, 2026|Endpoints News|
Illumina bets on healthcare after Trump administration’s NIH funding disruptionsnews2026-02-06T09:19:24+00:00February 6th, 2026|Endpoints News|
Hims adds Grail’s cancer test amid questions about widespread usenews2026-02-04T14:00:32+00:00February 4th, 2026|Endpoints News|
Labcorp backs Cellens in developing physics test aimed at bladder cancernews2025-12-23T14:00:11+00:00December 23rd, 2025|Endpoints News|
Hims launches lab testing for preventive carenews2025-11-13T17:00:04+00:00November 13th, 2025|Endpoints News|
